JY
OBIO icon

Jeff Yass’s Orchestra BioMed OBIO Stock Holding History

Jeff Yass’s Portfolio OBIO Stock Details OBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-60,100
Closed -$149K – 13209
2025
Q3 		$149K Buy
+60,100
New +$166K ﹤0.01% 11288

Other funds holding OBIO

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $191M AUM 102.42% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return

Jeff Yass's OBIO Position: Q2 2026 in Review

Jeff Yass reduced its Orchestra BioMed (OBIO) stake by 33% in Q2 2026, selling an estimated $130K and leaving 65,804 shares worth $284K. The position accounts for ﹤0.01% of the portfolio, ranked #11172.

Jeff Yass first reported a position in OBIO in Q3 2023 and has held it in 8 quarters since. The position peaked at $644K in Q4 2025. 76 funds tracked by Wall St. Rank hold OBIO as of Q2 2026.

  • Jeff Yass held 65,804 shares of Orchestra BioMed worth $284K as of Q2 2026.
  • Jeff Yass sold 31,717 Orchestra BioMed shares in Q2 2026, an estimated $130K.
  • Orchestra BioMed made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #11172 holding.
  • Jeff Yass first reported a position in Orchestra BioMed in Q3 2023 and has held it in 8 quarters since.
  • Jeff Yass's Orchestra BioMed position peaked at $644K in Q4 2025.
  • 76 funds tracked by Wall St. Rank held Orchestra BioMed as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.